At the Bench: Preclinical rationale for exploiting NK cells and γδ T lymphocytes for the treatment of high-risk leukemias.
about
Haploidentical Transplantation in Children with Acute Leukemia: The Unresolved IssuesRecent advances in haploidentical hematopoietic stem cell transplantation using ex vivo T cell-depleted graft in children and adolescentsCurrent perspectives on natural killer cell education and tolerance: emerging roles for inhibitory receptorsNatural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia.KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL.UV-inactivated HSV-1 potently activates NK cell killing of leukemic cells.BTN3A molecules considerably improve Vγ9Vδ2T cells-based immunotherapy in acute myeloid leukemiaAt the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies.Human NK cells: from surface receptors to the therapy of leukemias and solid tumorsCancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor ActivityHuman natural killer cells: news in the therapy of solid tumors and high-risk leukemias.γδ T cells in cancer.Vγ9Vδ2 T cells and zoledronate mediate antitumor activity in an orthotopic mouse model of human chondrosarcoma.CD19-specific triplebody SPM-1 engages NK and γδ T cells for rapid and efficient lysis of malignant B-lymphoid cells.NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia.Absolute Lymphocyte Count (ALC) after Induction Treatment Predicts Survival of Pediatric Patients with Acute Lymphoblastic Leukemia.Valproic Acid Combined with Zoledronate Enhance γδ T Cell-Mediated Cytotoxicity against Osteosarcoma Cells via the Accumulation of Mevalonate Pathway Intermediates.Haploidentical HCT using an αβ T-cell-depleted graft with targeted αβ(+) cells by add-back after a reduced intensity preparative regimen containing low-dose TBI.High-Risk Leukemia: Past, Present, and Future Role of NK Cells.γδ T cells: an immunotherapeutic approach for HIV cure strategies
P2860
Q26750671-83E0B8DB-2F91-4F4F-8AA4-33B8B8A23E80Q26750995-75EA3F53-3B37-4A06-9A04-4CD72D075BE5Q27009135-E7F7DD25-6753-425C-8643-C4E43CFE9449Q33734571-58F72FA8-63EE-4041-937C-AC216FA06597Q34398420-E9AF932E-AD81-4343-AEAB-EB754FE6ED23Q36966726-CEE5D0E8-EFE7-4639-9C65-D70D58FB8A2EQ37380386-D242707F-351D-4CCD-B759-6860F729AD93Q38149725-C0D4900D-EEE0-4470-8A3E-D7ABAC9A09AFQ38196803-21085BBB-6451-4F8F-9274-72163AA41B6BQ38203261-7366E3DC-2ED4-43C0-9AF4-1FE3EEE457D4Q38569646-530FF3EF-3CFD-4127-803C-9437361F91F0Q38602555-36054EE2-FACF-4763-BC92-1E250F7B13E8Q38811197-D3C41082-A334-40F6-9367-1D4DE5902A6DQ39204394-ADE57BCE-0140-4562-88F1-CF627E818624Q41472587-588E3ADA-E16D-42D1-B892-E0A09695BDE5Q50922836-C1F98F1D-AA3E-4CC4-8468-65E8DF8B5DC8Q52657143-EE9E150F-37E0-45DB-A184-542119AAB735Q53105512-EE73CCD7-0CEC-447D-8542-0F8EECAF3337Q55172823-9A8BFF30-5CDE-404B-AE35-2DBAA746F2D4Q57425152-FE0F45C3-800D-4331-B7A2-47B0E81ADF0B
P2860
At the Bench: Preclinical rationale for exploiting NK cells and γδ T lymphocytes for the treatment of high-risk leukemias.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
At the Bench: Preclinical rati ...... atment of high-risk leukemias.
@en
type
label
At the Bench: Preclinical rati ...... atment of high-risk leukemias.
@en
prefLabel
At the Bench: Preclinical rati ...... atment of high-risk leukemias.
@en
P2860
P356
P1476
At the Bench: Preclinical rati ...... atment of high-risk leukemias.
@en
P2093
Alessandro Moretta
Lorenzo Moretta
P2860
P304
P356
10.1189/JLB.0613312
P577
2013-10-09T00:00:00Z